The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Pharmacokinetics of metallic nanoparticles
Abstract
Metallic nanoparticles (NPs) have been widely applied in the field of nanomedicine. A comprehensive understanding of their pharmacokinetics is crucial for proper risk assessment and safe biomedical applications. This review focuses on gold and silver (Ag) NPs, and briefly discusses iron oxide, titanium dioxide (TiO 2), and zinc oxide NPs. Pharmacokinetics of metallic NPs depends on the particle type, size, surface charge, surface coating, protein binding, exposure route, dose, and species. Generally, blood half‐life is shorter in rodents than in larger laboratory animals (e.g., rabbits or monkeys) and differs between intravenous and oral exposures. Oral, dermal, or inhalational absorption is low (≤5%), but may increase with smaller sizes, negative charge, and appropriate coatings. Metallic NPs can be distributed throughout the body, primarily accumulating in the liver, spleen, and lymph node due to nonspecific uptake by reticuloendothelial cells, and could remain in the body for ≥6 months. Metallic NPs (≤100 nm) can cross the blood–brain barrier (BBB), favored by coating with BBB‐permeable neuropeptides. Placental transfer depends on the stage of embryonic/placental maturation and surface composition, and may be enhanced by coating with biocompatible molecules (e.g., ferritin or polyethylene glycol). Renal and biliary excretion is generally low due to persistent accumulation in tissues, but renal elimination could be substantially increased with smaller sizes and specific coatings (e.g., glutathione). Physiologically based pharmacokinetic models for gold/dendrimer composite nanodevices, AgNPs, and TiO 2 NPs have been developed in rats and the AgNP and TiO 2 NP models have been extrapolated to humans to support risk assessment and nanomedicine applications. WIREs Nanomed Nanobiotechnol 2015, 7:189–217. doi: 10.1002/wnan.1304 This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Laurent, S., Forge, D., Port, M., Roch, A., Robic, C., Vander Elst, L., & Muller, R. N. (2008) · Chemical Reviews · doi:10.1021/cr068445e · Cited by 6,852
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration
De Jong, W. H., Hagens, W. I., Krystek, P., Burger, M. C., Sips, A. J. A. M., & Geertsma, R. E. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.037 · Cited by 1,615
Khlebtsov, N., & Dykman, L. (2011) · Chem. Soc. Rev. · doi:10.1039/c0cs00018c · Cited by 1,584
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
WANG, J., ZHOU, G., CHEN, C., YU, H., WANG, T., MA, Y., JIA, G., GAO, Y., LI, B., & SUN, J. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2006.12.001 · Cited by 1,145
Sonavane, G., Tomoda, K., & Makino, K. (2008) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2008.07.004 · Cited by 1,100
Introduction to metallic nanoparticles
Mody, V., Siwale, R., Singh, A., & Mody, H. (2010) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.72127 · Cited by 1,025
Johnston, H. J., Hutchison, G., Christensen, F. M., Peters, S., Hankin, S., & Stone, V. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408440903453074 · Cited by 930
Cited by
Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements
Her, S., Jaffray, D. A., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.012 · Cited by 865
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Titanium Dioxide Nanoparticles – Prospects and Applications in Medicine
Ziental, D., Czarczynska-Goslinska, B., Mlynarczyk, D. T., Glowacka-Sobotta, A., Stanisz, B., Goslinski, T., & Sobotta, L. (2020) · doi:10.20944/preprints202002.0271.v1 · Cited by 721
Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
Lee, N.-Y., Ko, W.-C., & Hsueh, P.-R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01153 · Cited by 532
Pharmaceutical aspects of silver nanoparticles
Mathur, P., Jha, S., Ramteke, S., & Jain, N. K. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2017.1414825 · Cited by 362
Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A., & Lin, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b08142 · Cited by 362
Self-citationGlutathione: Antioxidant Properties Dedicated to Nanotechnologies
Gaucher, C., Boudier, A., Bonetti, J., Clarot, I., Leroy, P., & Parent, M. (2018) · Antioxidants · doi:10.3390/antiox7050062 · Cited by 332
Mba, I. E., & Nweze, E. I. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03070-x · Cited by 321
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Active targeting of gold nanoparticles as cancer therapeutics
Goddard, Z. R., Marín, M. J., Russell, D. A., & Searcey, M. (2020) · Chemical Society Reviews · doi:10.1039/d0cs01121e · Cited by 282
In vitro assessment of silver nanoparticles immunotoxicity
Galbiati, V., Cornaghi, L., Gianazza, E., Potenza, M. A., Donetti, E., Marinovich, M., & Corsini, E. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.12.023 · Cited by 35
Insights on drug and gene delivery systems in liver fibrosis
Vyas, K., & Patel, M. M. (2023) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2023.100779 · Cited by 30
Zhang, J., Lu, L., Zhang, W., Miao, Y., Du, H., Xia, H., Tao, Z., Du, Z., Tang, Y., & Fang, Q. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114374 · Cited by 7
Metadata
- Authors
- Lin, Z., Monteiro‐Riviere, N. A., & Riviere, J. E.
- Venue
- WIREs Nanomedicine and Nanobiotechnology
- Publisher
- Wiley
- Published
- 2014-10-15
- Volume
- 7
- Issue
- 2
- Pages
- 189-217
- ISSN
- 1939-0041 (ISSN-L)
- 1939-5116
- OpenAlex
- W2120553873
- Cited by
- 257
- References
- 133
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.